ontained in this communication as new information becomes available.


View source version on businesswire.com: https://www.businesswire.com/news/home/20260429263104/en/


CONTACT:

Press Info:

Chiesi Group Contacts:

Anna Bonisoli Alquati, Head of Global External Communications: mediarelations@chiesi.com
Chiara Travagin, Head of Global Communications, Rare: mobile +39 348.8818985, e-mail: c.travagin@chiesi.com
Michela Lijoi, Global External Communications Sr. Manager: mobile +39 328.6353044, e-mail: m.lijoi@chiesi.com

KalVista Contacts:

Ryan Baker
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com

Molly Cameron
Senior Director, Corporate Affairs
(978) 339-3378
molly.cameron@kalvista.com
Chiesi agreed to acquire KalVista Pharmaceuticals for ￥27.00 per share in cash, representing an equity consideration of approximately ￥1.9bn Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for here
=*=*=*=*=*=
当前为第20/21页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页